<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">982606</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2022.982606</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>More than a duologue: In-depth insights into epitranscriptomics and ferroptosis</article-title>
<alt-title alt-title-type="left-running-head">Cheung et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2022.982606">10.3389/fcell.2022.982606</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cheung</surname>
<given-names>Justin Chak Ting</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1893724/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Guangzheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wong</surname>
<given-names>Nathalie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dong</surname>
<given-names>Yujuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1579005/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ng</surname>
<given-names>Simon Siu Man</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/127960/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Surgery</institution>, <institution>Prince of Wales Hospital</institution>, <institution>The Chinese University of Hong Kong</institution>, <addr-line>Shatin</addr-line>, <country>Hong Kong SAR, China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>CUHK-Shenzhen Research Institute</institution>, <institution>The Chinese University of Hong Kong</institution>, <addr-line>Shatin</addr-line>, <country>Hong Kong SAR, China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1459808/overview">Xichen Bao</ext-link>, Guangzhou Institutes of Biomedicine and Health (CAS), China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1606053/overview">Baofa Sun</ext-link>, Nankai University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1045019/overview">Jiangbo Wei</ext-link>, The University of Chicago, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Simon Siu Man Ng, <email>simonng@surgery.cuhk.edu.hk</email>; Yujuan Dong, <email>yjdong@surgery.cuhk.edu.hk</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>982606</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>06</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>08</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Cheung, Deng, Wong, Dong and Ng.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Cheung, Deng, Wong, Dong and Ng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Beyond transcription, RNA molecules are enzymatically modified to influence the biological functions of living organisms. The term &#x201c;epitranscriptomics&#x201d; describes the changes in RNA strands aside from altering the innate sequences. Modifications on adenosine (A) are the most widely characterized epitranscriptomic modification, including N<sup>6</sup>-methyladenosine (m<sup>6</sup>A), N<sup>1</sup>-methyladenosine (m<sup>1</sup>A), polyadenylation, and adenosine-to-inosine (A-to-I) RNA editing, and modifications on other nucleotides seem to be fewer, such as N<sup>7</sup>-methylguanosine (m<sup>7</sup>G), 5-methylcytosine (m<sup>5</sup>C), and pseudouridine (&#x3a8;). These changes on the RNA strand surface, exclusively by their RNA-modifying proteins (RMPs), are reported in various biological phenomena, including programmed cell death (PCD). One necro-biological phenomenon that has been observed for long but has started to gain heed in recent years is &#x201c;<italic>ferroptosis</italic>.&#x201d; The phospholipid peroxidation by polyunsaturated-fatty-acid-containing-phospholipid hydroperoxyl (PLOOH) radicals destroys membrane integrity due to a series of mechanisms. The Fenton reaction, constituting the final Haber&#x2013;Weiss reaction that is less recognized, collaboratively leading to the conversion of polyunsaturated fatty acid (PUFA) to PLOOH, is the etymological origin of ferroptosis. However, it is with increasing evidence that ferroptotic signaling is also intervened by epitranscriptomic modifications, although the truth is still ambiguous. We attempted to delineate some up-to-date discoveries on both epitranscriptomics and ferroptosis, bringing up the fundamentals to address any potential connection between the two. Next, we discussed whether a duologal relationship, or more, exists between the two, taking the ROS level and iron status into consideration. Lastly, we surveyed future perspectives that would favor the understanding of these topics.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FCELL_fcell-2022-982606_wc_abs.tif" position="anchor"/>
</p>
</abstract>
<kwd-group>
<kwd>ferroptosis</kwd>
<kwd>epitranscriptomics</kwd>
<kwd>iron metabolism</kwd>
<kwd>lipid peroxidation</kwd>
<kwd>reactive oxygen species</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The RNA world theory hypothesized that every living matter originated from RNA as the entity of evolutionary heredity, in lieu of DNA (<xref ref-type="bibr" rid="B58">Rana &#x26; Ankri, 2016</xref>). After that, a myriad of scientists have boosted our awareness of RNA through their work and established the principles underlining the <italic>Central Dogma</italic> of molecular biology. Nevertheless, beyond transcription, RNA molecules can also be enzymatically modified, building a new field of epitranscriptomics that is currently under intense interest. These modifications are reported in various physiological and pathological processes, which are reviewed brilliantly elsewhere, such as tRNA modifications in the role of development (<xref ref-type="bibr" rid="B21">Frye et al., 2018</xref>) and transcriptional and chromatin regulation by m<sup>6</sup>A (<xref ref-type="bibr" rid="B75">Wei &#x26; He, 2021</xref>) (<xref ref-type="bibr" rid="B64">Shi et al., 2019</xref>). Moreover, their respective RNA-modifying proteins (RMPs) are also the targets for the investigation of epitranscriptomic regulations (<xref ref-type="bibr" rid="B64">Shi et al., 2019</xref>). Specific to oncological research, these RNA-modifying processes are often hijacked in cancers to acquire pro-survival advantages, and aberrant epitranscriptomic modifications have been implicated in resistance to programmed cell death (PCD). Ferroptosis, a new type of PCD denoted by an iron-dependent lethal accumulation of lipid peroxides, has started to gain heed in recent years. The complexity in ferroptotic signaling has indeed offered more opportunities for potential therapeutic manipulations in treating cancer. We attempted to delineate the up-to-date discoveries on both epitranscriptomics and ferroptosis, bringing up the fundamentals to address any potential connection between the two. Next, we discussed whether a duologal relationship, or more, exists between the two, taking the ROS level and iron status into consideration. Lastly, we surveyed future perspectives that would favor the understanding of these topics.</p>
</sec>
<sec id="s2">
<title>Beyond transcriptomics: epitranscriptomics</title>
<p>RNA comprises several kinds of modifications on the transcripts that constitute the epitranscriptome. The enzyme-mediated covalent modifications on RNA, also termed epitranscriptomic modifications, experienced an arduous period after the pioneering discovery of pseudouridine (&#x3c8;) in 1951 by Davis and Ellen as the first epitranscriptomic modification (<xref ref-type="bibr" rid="B7">Davis &#x26; Allen, 1957</xref>). After the early work from <xref ref-type="bibr" rid="B57">Perry &#x26; Kelley, (1974</xref>) proving the existence of an mRNA epitranscriptomic modification in mouse L-cells, it has then become clearer that the life cycle of an mRNA transcript does not merely experience transcription but also posttranscriptional processing such as 5&#x2032;-capping, poly-adenylation, and most importantly in the context of this article, epitranscriptomic modifications.</p>
<p>Epitranscriptomic modifications are observed in both coding mRNA transcripts (<xref ref-type="bibr" rid="B21">Frye et al., 2018</xref>) (<xref ref-type="bibr" rid="B23">Gilbert et al., 2016</xref>) and non-coding RNA, such as long non-coding RNA (lncRNA) (<xref ref-type="bibr" rid="B87">Yin et al., 2021</xref>), microRNA (miRNA) (<xref ref-type="bibr" rid="B37">Konno et al., 2019</xref>), and transfer RNA (tRNA) (<xref ref-type="bibr" rid="B56">Pereira et al., 2018</xref>). Dysregulated epitranscriptomic modifications on both coding mRNA and tRNA have been intuitively considered signatures in pathologies (<xref ref-type="bibr" rid="B8">Destefanis et al., 2021</xref>) (<xref ref-type="bibr" rid="B68">Suzuki, 2021</xref>) (<xref ref-type="bibr" rid="B84">Yang et al., 2020</xref>). Specifically, posttranscriptional editing determines the RNA fate through mediating cellular processes, including alternative splicing (<xref ref-type="bibr" rid="B78">Xue et al., 2021</xref>), nonsense-mediated mRNA decay (<xref ref-type="bibr" rid="B42">Li et al., 2019a</xref>), and translation (<xref ref-type="bibr" rid="B59">Ranjan &#x26; Leidel, 2019</xref>). Extending to biological functions, the epitranscriptome has built its niche in physiological regulation, which is exemplified by circadian rhythm regulation by A-to-I editing catalyzing the ADAR enzyme family (<xref ref-type="bibr" rid="B69">Terajima et al., 2017</xref>), GBM-associated protein expression upregulated by METTL3 via SOX2 (<xref ref-type="bibr" rid="B72">Visvanathan et al., 2018</xref>), and poor prognostic characterization through the IGF2BP/SOX2/METTL3 axis in CRC (<xref ref-type="bibr" rid="B44">Li et al., 2019b</xref>).</p>
<sec id="s2-1">
<title>Epitranscriptomic signatures and RNA-modifying proteins</title>
<p>According to MODOMICS, an RNA modification database constructed by Boccaletto et al. few years ago, documented RNA modifications have now raised to 144 (<xref ref-type="bibr" rid="B17">Dunin-Horkawicz et al., 2006</xref>), and the upsurge continues due to improved sequencing techniques and other technological advancements. To date, discussions on RNA modifications mainly revolve around the well-characterized ones, including N<sup>6</sup>-methyladenosine (m<sup>6</sup>A), 5-methylcytosine in RNA (m<sup>5</sup>C), N<sup>1</sup>-methyladenosine (m<sup>1</sup>A), and pseudouridine (&#x3a8;). Others like 5-hydroxymethylcytosine (5-hmC), N<sup>4</sup>-acetylcytidine (ac<sup>4</sup>C), and adenosine-to-inosine editing (A-to-I) are only registered with unknown or unspecified functions. Moreover, MODOMICS covers the related diseases and pathways (<xref ref-type="bibr" rid="B17">Dunin-Horkawicz et al., 2006</xref>), with sequential updates at regular intervals (<xref ref-type="bibr" rid="B52">Machnicka et al., 2013</xref>) (<xref ref-type="bibr" rid="B3">Boccaletto et al., 2018</xref>), leading to more attention directed to the rising role of RNA modifications contributing to the nuanced transcriptomic homeostasis from clinicians and scientists (<xref ref-type="bibr" rid="B65">Song et al., 2020</xref>).</p>
<p>The fate of an mRNA transcript is determined by a series of events posttranscriptionally, and one of such crucial processes is epitranscriptomic modifications. In general, the process of mRNA epitranscriptomic editing relies on three major types of RNA-modifying proteins (RMPs):<list list-type="simple">
<list-item>
<p>1) writers that deposit RNA modifications, for e.g., methyltransferase-like (METTL) enzyme family members, zinc finger CCCH-type containing 13 (ZC3H13), and VIRMA/KIAA1429 for m<sup>6</sup>A, TRMT family members for m<sup>1</sup>A, ADARs for A-to-I editing, and NSUNs for m<sup>5</sup>C;</p>
</list-item>
<list-item>
<p>2) erasers that remove the epitranscriptomic modifications, for e.g., fat mass- and obesity-associated protein (FTO) for m<sup>6</sup>A and AlkB homologs (ALKBH) for m<sup>1</sup>A, m<sup>6</sup>A, and m<sup>5</sup>C;</p>
</list-item>
<list-item>
<p>3) readers that are recruited and recognize the modifications to alter the fate of mRNA transcripts, for e.g., YT521-B homology (YTH) domain family members for m<sup>6</sup>A and Aly/REF export factor (ALYREF) for m<sup>5</sup>C.</p>
</list-item>
</list>
</p>
<p>RNAWRE, which was constructed in 2020 by <xref ref-type="bibr" rid="B54">Nie et al. (2020</xref>) and apropos to mention, comprises more than 2000 manually curated writers, erasers, and readers. RMP regulation determines whether the previously mentioned epitranscriptomic signatures are installed, removed, or recognized. By dint of <xref ref-type="table" rid="T1">Table 1</xref> summary and <xref ref-type="fig" rid="F1">Figure 1</xref> illustration, types of epitranscriptomic marks and their respective RMPs will not be outlined thoroughly in paragraphs. The concept of how these epitranscriptomic marks and RMP expression affect the existence and severity of ferroptosis will be discussed in later parts and illustrated in the compiled figures.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Examples of RNA-modifying proteins and associated epitranscriptomic modifications.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Nucleoside execution-on</th>
<th align="left">Type of epitranscriptomic modification</th>
<th align="left">Location (s)</th>
<th align="left">Writer</th>
<th align="left">Reader</th>
<th align="left">Eraser</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="9" align="left">Adenosine (A)</td>
<td rowspan="5" align="left">N6-Methyladenosine (m<sup>6</sup>A)</td>
<td rowspan="5" align="left">mRNA, rRNA, snRNA, and tRNA</td>
<td align="left">METTL family members: METTL3-METTL14 heterodimer (assisted by WTAP interacting with VIRMA), METTL4, METTL5&#x2013;TRMT112 complex, and METTL16</td>
<td align="left">YTHs (YTHDF1/2/3, YTHDC1 with SRSF3, and NXF1 and YTHDC2)</td>
<td align="left">FTO (guided by SFPQ)</td>
</tr>
<tr>
<td align="left">ZC3H13 corporation: ZC3H13-RBM15/RBM15B ZC3H13-WTAP</td>
<td align="left">HNRNP (HNRNPA2B1/C/G)</td>
<td rowspan="4" align="left">ALKBH5</td>
</tr>
<tr>
<td align="left">VIRMA/KIAA1429</td>
<td align="left">IGF2BPs (IGF2BP1/2/3)</td>
</tr>
<tr>
<td align="left">CBLL1/HAKAI</td>
<td rowspan="2" align="left">NKAP</td>
</tr>
<tr>
<td align="left">ZCCHC4</td>
</tr>
<tr>
<td rowspan="2" align="left">N1-Methyladenosine (m1A)</td>
<td rowspan="2" align="left">tRNA, mRNA, and rRNA</td>
<td align="left">TRMT family members: TMRT10C and TRMT6-TRMT61A orthologs</td>
<td rowspan="2" align="left">YTHDF3</td>
<td align="left">ALKBH1 and ALKBH3</td>
</tr>
<tr>
<td align="left">m1A58 MTase</td>
<td align="left">FTO</td>
</tr>
<tr>
<td align="left">A-to-I editing</td>
<td align="left">mRNA</td>
<td align="left">ADARs (ADAR1/2/3)</td>
<td align="left">&#x2014;</td>
<td align="left">&#x2014;</td>
</tr>
<tr>
<td align="left">N6,2&#x2032;-O-Dimethyladenosine (m<sup>6</sup>Am)</td>
<td align="left">mRNA</td>
<td align="left">PCIF1</td>
<td align="left">&#x2014;</td>
<td align="left">FTO</td>
</tr>
<tr>
<td rowspan="7" align="left">Cytidine (C)</td>
<td rowspan="4" align="left">5-methylcytosine (m5C)</td>
<td rowspan="4" align="left">mRNA, tRNA, rRNA, and ncRNA</td>
<td align="left">NSUNs (NSUN1/2/3/4/5/6/7)</td>
<td rowspan="2" align="left">ALYREF</td>
<td rowspan="2" align="left">TETs (TET1/2/3)</td>
</tr>
<tr>
<td align="left">DNMT2</td>
</tr>
<tr>
<td align="left">TRDMT1</td>
<td rowspan="2" align="left">YBX1</td>
<td rowspan="2" align="left">ALKBH1</td>
</tr>
<tr>
<td align="left">TRM4A/4B</td>
</tr>
<tr>
<td align="left">N4-Acetylcytosine (ac<sup>4</sup>C)</td>
<td align="left">rRNA and tRNA</td>
<td align="left">NAT10</td>
<td align="left">&#x2014;</td>
<td align="left">&#x2014;</td>
</tr>
<tr>
<td rowspan="2" align="left">3-Aethylcytidine (m<sup>3</sup>C)</td>
<td rowspan="2" align="left">rRNA, tRNA, and mRNA</td>
<td align="left">METTL2/6 (tRNA)</td>
<td rowspan="2" align="left">&#x2014;</td>
<td rowspan="2" align="left">ALKBH1</td>
</tr>
<tr>
<td align="left">METTL8 (mRNA)</td>
</tr>
<tr>
<td rowspan="3" align="left">Uridine (U)</td>
<td rowspan="3" align="left">Pseudouridine (&#x3a8;)</td>
<td rowspan="3" align="left">rRNA, tRNA, mRNA, and snRNA</td>
<td align="left">PUS1/2/3/4/6/7/9</td>
<td rowspan="3" align="left">&#x2014;</td>
<td rowspan="3" align="left">&#x2014;</td>
</tr>
<tr>
<td align="left">TRUB1</td>
</tr>
<tr>
<td align="left">DKC1</td>
</tr>
<tr>
<td rowspan="3" align="left">Guanine (G)</td>
<td align="left">7-Methylguanosine (m7G)</td>
<td align="left">mRNA, tRNA, rRNA, and miRNA</td>
<td align="left">METTL1/WDR4</td>
<td align="left">&#x2014;</td>
<td align="left">&#x2014;</td>
</tr>
<tr>
<td align="left">N2-methylguanosine (m<sup>2</sup>G)</td>
<td align="left">tRNA and rRNA</td>
<td align="left">rRNA (guanine-N2-)-methyltransferase</td>
<td align="left">&#x2014;</td>
<td align="left">&#x2014;</td>
</tr>
<tr>
<td align="left">Queuine (Q)</td>
<td align="left">tRNA</td>
<td align="left">TGT</td>
<td align="left">&#x2014;</td>
<td align="left">&#x2014;</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Illustration of RNA-modifying proteins on mRNA and common RNA modifications. Common base modifications include N<sup>6</sup>&#x2013;methyladenosine (m<sup>6</sup>A), N<sup>1</sup>&#x2013;methyladenosine (m<sup>1</sup>A), pseudouridine (&#x3c8;), and 5&#x2013;methycytosine (m<sup>5</sup>C), to name but a few. Less common modifications are also listed in the illustration. RNA-modifying proteins that govern the expression of the mRNA transcript by manipulating epitranscriptomic sites include (1) writers that deposit RNA modifications, (2) erasers that remove the epitranscriptomics modifications, and (3) readers that are recruited and recognize the modifications to alter the fate of transcripts. Reprinted from &#x201C;Common eukaryotic mRNA modifications&#x201D;, by <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://BioRender.com">BioRender.com</ext-link> (2020). Retrieved from <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://app.biorender.com/biorender-templates">https://app.biorender.com/biorender-templates</ext-link>.</p>
</caption>
<graphic xlink:href="fcell-10-982606-g001.tif"/>
</fig>
</sec>
<sec id="s2-2">
<title>Detecting epitranscriptomics modifications</title>
<p>Even though the adjustments on nucleotides seem slight and minuscule, finding a way to elucidate the epitranscriptomic marks is never simple and uncomplicated. Consecutive efforts are required owing to these nanoscopic modifications down to nucleotides. This review will not focus on the in-depth discussion of epitranscriptomic mark detection, given that such an issue has already been brilliantly reviewed elsewhere (<xref ref-type="bibr" rid="B28">Helm &#x26; Motorin, 2017</xref>) (<xref ref-type="bibr" rid="B61">Sarkar et al., 2021</xref>). Nevertheless, we shall highlight the important ones, including NGS-based techniques or mass spectrometry-based techniques.</p>
<sec id="s2-2-1">
<title>Next-generation sequencing-based techniques</title>
<p>AlkB-facilitated RNA methylation sequencing (ARM-seq) (<xref ref-type="bibr" rid="B6">Cozen et al., 2015</xref>), combines reverse transcription (RT) and enzymatic demethylation and relies on detecting truncations due to existing methylated nucleosides during RT. Localization of truncations from high-throughput sequencing navigates the potential methylated sites in RNA transcripts, except when the reaction reaches RT-silent bases such as pseudouridine, ribothymidine, or m<sup>5</sup>C. Aside from RT-methods, antibody-dependent assays like m<sup>6</sup>A-seq (for m<sup>6</sup>A) or m<sup>1</sup>A-seq (for m<sup>1</sup>A), MeRIP-seq (<xref ref-type="bibr" rid="B15">Dominissini et al., 2015</xref>), CLIP-based strategies (<xref ref-type="bibr" rid="B35">Ke et al., 2015</xref>), PAR-CLIP&#x2013;MeRIP (<xref ref-type="bibr" rid="B48">Liu et al., 2015</xref>), miCLIP (for methylated nucleosides in RNA) (<xref ref-type="bibr" rid="B26">Hawley &#x26; Jaffrey, 2019</xref>), and suicide enzyme trap (for identification of methyltransferase targets on RNA strands) (<xref ref-type="bibr" rid="B36">Khoddami &#x26; Cairns, 2013</xref>) have also revolutionized the epitranscriptomic mark detection. By eliminating the possibility of having RT-arrest and mis-incorporation of nucleosides during RT like RT-based detection, enrichment-based methods stand out with their superb specificity to methylated nucleosides.</p>
</sec>
<sec id="s2-2-2">
<title>Mass spectrometry-based techniques</title>
<p>Dating back to 1977, McCloskey and Nishimura were the first to utilize MS to detect tRNA modifications down to nucleoside resolution. The RNA MS regimen relies on enzymatic digestion/reduction of RNA strands to nucleosides/nucleotides with the nucleic acid backbone being eliminated, and the downward workflow is analogous to metabolite MS, including ionizing the compound and deflecting the molecule in an electric field, followed by a magnetic field. The determination of an m/z ratio greatly depends on retention time, molecular mass, and fragmentation patterns in tandem mass spectrometry (MS/MS) for the identification of modification residues (<xref ref-type="bibr" rid="B28">Helm &#x26; Motorin, 2017</xref>). Variations of MS include combination with liquid chromatography purification on RNA fragments <italic>a posteriori</italic> nuclease such as RNase T1 and MC1, followed by electrospray ionization (ESI) and MS/MS, entitled LC-ESI-MS/MS (<xref ref-type="bibr" rid="B89">Yuan, 2017</xref>). Two years ago, <xref ref-type="bibr" rid="B76">Wein et al. (2020</xref>) constructed an open-source database for documenting RNA MS data named NucleicAcidSearchEngine (NASE). <xref ref-type="bibr" rid="B27">Heiss et al. (2021</xref>) have also recreated LC-MS/MS by combining nucleic acid isotope labeling (NAIL) and MS, entitled NAIL-MS, to address the dynamic nature of epitranscriptomic modifications that the currently available MS protocols lack the ability to tackle. Nonetheless, despite the comprehensiveness offered by MS, respective localization of modifications in the RNA environment will be completely lost and irretrievable.</p>
</sec>
</sec>
</sec>
<sec id="s3">
<title>Ironing out the iron: investigating ferroptosis</title>
<p>The first observation on erastin-induced lethality in engineered Ras-mutant human foreskin fibroblasts discovered distinctive morphological features and biochemical machineries compared to traditional programmed cell death (PCD). <italic>Ferroptosis</italic>, coined in 2012 under the work of <xref ref-type="bibr" rid="B10">Dixon et al. (2012</xref>), has shed light on the field of PCD and has, henceforth, attracted heed from cell biologists. Devoid of apoptotic morphological features, such as apoptotic body formation or nuclear fragmentation, ferroptotic cells are characterized by increased mitochondrial densities and reduction of mitochondrial crista that are not observed in the conventional PCD (<xref ref-type="bibr" rid="B43">Li et al., 2020</xref>). The discovery of iron chelation also denoted an unprecedented biochemical pathway in regulating ferroptosis. Even so, much of our knowledge in ferroptosis is still not complete nor is satisfactory enough to intervene this mechanistic pathway in the current clinical settings.</p>
<p>In the history of ferroptosis characterization, the pioneering finding of erastin has led to the comprehensive dissection of ferroptosis in recent years. Large-scale screening experiments in surveying the killing effects of a multitude of compounds exerted on cancer cells <italic>via</italic> mitochondrial voltage-dependent anion channels, conducted by <xref ref-type="bibr" rid="B14">Dolma et al. (2003</xref>), have directed the very first discovery of erastin. Few years afterward, erastin treatment was investigated, and the results of lipid-related oxidative stress were noticed by <xref ref-type="bibr" rid="B79">Yagoda et al. (2007</xref>). The RAS-selective lethal 3 (RSL3) was brought up in 2008 from another large-scale synthetic lethal screening by <xref ref-type="bibr" rid="B83">Yang &#x26; Stockwell (2008</xref>) in the presence of RAS (therefore, the nomenclature). <xref ref-type="bibr" rid="B10">Dixon et al. (2012</xref>) officially entitled this iron-dependent cell death as &#x201c;<italic>ferroptosis</italic>&#x201d;. Successful characterization has then propagated more in-depth discoveries, including ferrostatin-1 (fer-1) inhibition of ferroptosis, mitochondria independency (<xref ref-type="bibr" rid="B22">Gaschler et al., 2018</xref>), sorafenib induction of ferroptosis (<xref ref-type="bibr" rid="B39">Lachaier et al., 2014</xref>) (<xref ref-type="bibr" rid="B50">Louandre et al., 2013</xref>), system X<sub>c</sub>
<sup>&#x2212;</sup> being inhibited by erastin (<xref ref-type="bibr" rid="B11">Dixon et al., 2014</xref>) (grounded in the fact that cystine deprivation leads to glutathione-dependent cell death long before the characterization of ferroptosis (<xref ref-type="bibr" rid="B18">Eagle, 1955</xref>) (<xref ref-type="bibr" rid="B29">Hinson et al., 2010</xref>)), glutathione peroxidase 4 (GPX4) participation (<xref ref-type="bibr" rid="B82">Yang et al., 2014</xref>), and enormous regulatory ferroptotic inducers (other than erastin, e.g., DPIs, FIN56, and FINO2) and inhibitors (e.g., iron chelators, vitamin E, SRS8-24, and CA-1).</p>
<sec id="s3-1">
<title>Delineating the mechanisms of ferroptosis</title>
<p>Ferroptosis starts with the production of lipid peroxides as a general cellular suicidal program with an iron-mediated oxidative mechanism. Cellular reactions exhibit redox equilibrium, and disruption of redox equilibrium is attributed to the synthesis and accumulation of reactive oxygen species. Definitive ROS, including superoxide anion (O<sub>2</sub>
<sup>&#x2212;</sup>&#x2022;), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), hydroxyl radicals (HO&#x2022;), hydroperoxides (ROOH), and hydroxyl radicals (ROO&#x2022;), are formed by partial reduction of oxygen. ROS are generated inevitably from oxidative phosphorylation in mitochondria to cellular respiration, and the endogenous antioxidant system is instrumental to remove the oxidative stress. It has been held as an axiom that ROS accumulation also lays the groundwork of multiple pathologies, given its roles in cellular damage in diabetic cardiomyopathy (<xref ref-type="bibr" rid="B34">Kaludercic &#x26; Di Lisa, 2020</xref>), atherosclerosis (<xref ref-type="bibr" rid="B85">Yang et al., 2017</xref>), neurological complications (<xref ref-type="bibr" rid="B53">Manoharan et al., 2016</xref>), and in cell growth, especially in cancers (<xref ref-type="bibr" rid="B1">Aggarwal et al., 2019</xref>) (<xref ref-type="bibr" rid="B9">Dias Amoedo et al., 2020</xref>) (<xref ref-type="bibr" rid="B70">Tien Kuo &#x26; Savaraj, 2006</xref>) (<xref ref-type="bibr" rid="B92">Zeng et al., 2021</xref>). A detailed mechanistic overview of ferroptosis is illustrated in <xref ref-type="fig" rid="F2">Figure 2</xref>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Pathways of ferroptosis. The entirety of ferroptosis signaling is complex and orchestrated by different sub-pathways, along with a multitude of regulatory proteins or substances. The antioxidant system starts with system xc<sup>&#x2212;</sup> activity that assists the exchange of cystine and glutamate. Intracellular cystine is converted, in multi-step reactions, to GSH. The transsulfuration reaction starts with conversion of intracellular methionine to cysteine and joins the antioxidant system to enhance GSH production. Lipid ROS production from membrane PUFAs, intracellular lipid droplets, and acetyl-CoA resulted from mitochondrial aerobic respiration, which is negatively regulated by lipophagy, provides predominant lipid source to produce lipid ROS by joining the Fenton/Haber&#x2013;Weiss reaction. Iron metabolism starts with Fe<sup>3&#x2b;</sup> endocytosis initiated by a transferrin receptor, and STEAP3-mediated reduction to Fe<sup>2&#x2b;</sup> takes place in endosome. Fe<sup>2&#x2b;</sup> joins LIP by FTH1/FTL. Ferritinophagy triggers the release of Fe<sup>2&#x2b;</sup> to join intracellular ROS pool and proceeds to the Fenton/Haber&#x2013;Weiss reaction to produce lipid ROS. Taken together, the PUFA-PLOOH resulting from the reactions induces ferroptotic damage with the mechanism that lacks exactitude. Created with <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p>
</caption>
<graphic xlink:href="fcell-10-982606-g002.tif"/>
</fig>
<p>What lies at the cardiac part of this cellular iron-mediated killing is lipid ROS. The most abundant ROS, superoxide, is generated by cytochrome P450 and NADPH oxidases (NOXs) partial reduction, forming H<sub>2</sub>O<sub>2</sub> by superoxide dismutase (SOD), and the anions proceed to the production of hydroxyl radicals with the catalytic role of iron. In fact, published articles only documented the iron participation as the Fenton reaction, and the final Haber&#x2013;Weiss reaction, obtained after balancing chemical equations from Fenton and the others, was less recognized than the Fenton reaction. Ferrous ions (Iron (II) or Fe<sup>2&#x2b;</sup>) are mainly produced from the labile iron pool (LIP) and upon radical attack to heme groups with iron&#x2013;sulfur (Fe&#x2013;S) clusters (<xref ref-type="bibr" rid="B24">Gomez et al., 2014</xref>). Oxidation of ferrous to ferric ion (iron (III) or Fe<sup>3&#x2b;</sup>) facilitates free radical formation from H<sub>2</sub>O<sub>2</sub>, whilst the O<sub>2</sub>
<sup>&#x2212;</sup>&#x2022; radicals are also oxidized to harmless O<sub>2</sub> as a net Haber&#x2013;Weiss reaction. Taken together, the iron-mediated production of hydroxyl radicals is a &#x201c;superoxide-driven Fenton-catalyzing Haber&#x2013;Weiss reaction,&#x201d; or Fenton/Haber&#x2013;Weiss reaction, as illustrated in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Fenton/Haber&#x2013;Weiss reaction. Created with <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p>
</caption>
<graphic xlink:href="fcell-10-982606-g003.tif"/>
</fig>
<p>After the Paleoproterozoic Great Oxygenation Event (GOE), lives on the earth were subjected to oxidation readily, especially for polyunsaturated lipids with bis-allylic carbons (<xref ref-type="bibr" rid="B73">Wagner et al., 1994</xref>). The victim of such ROS attack in ferroptosis after all the aforementioned series of events is, therefore, polyunsaturated fatty acids (PUFAs). Under normal physiology, PUFAs, including arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are situated in the cell membrane. The attack from accumulating free radicals to PUFAs, otherwise named peroxidation reaction, generates phospholipid free radicals (PL&#x2022;) and, therefore, PUFA-containing-phospholipid hydroperoxides (PL-PUFA (PE)-OOH, PLOOH in short) (<xref ref-type="bibr" rid="B20">Forcina &#x26; Dixon, 2019</xref>), facilitated by different lipoxygenases (LOXs). It was also demonstrated that depletion of an acyl-CoA synthetase ACSL4 and LPCAT3 esterification enzyme inhibited ferroptosis (<xref ref-type="bibr" rid="B13">Doll et al., 2017</xref>) (<xref ref-type="bibr" rid="B90">Yuan et al., 2016</xref>). PLOOHs execute the unelucidated last hit to the cell membrane and initiate disruption to cellular integrity, leading to ferroptosis.</p>
<p>The transmembrane cystine/glutamate exchanger commences the work to initiate a ferroptosis-specific antioxidant system. System x<sub>c</sub>
<sup>&#x2212;</sup>, which was found to be inhibited by erastin, serves as an amino acid homeostatic control with the exchange of extracellular L-cystine and intracellular L-glutamate. Dissecting the antiporter, it consists of two subunits, a light chain solute carrier family 7 member 11 (SLC7A11) and a heavy chain subunit SLC family 3 member 2 (SLC3A2), which are targeted by respective inhibitors. Intracellular cysteine from cystine reduction facilitates the production of glutathione (GSH) that is catalyzed by glutamate&#x2013;cysteine ligase catalytic subunit (GCLC) (which is inhibited by buthionine sulfoximine (BSO)) and then by glutathione synthetase (GSS). The classical redox-associated glutathione system (GSH and oxidized GSH disulfide (GSSG)) comes in to play a role in antioxidant defense, proven back in the 90s (<xref ref-type="bibr" rid="B4">Ceballos-Picot et al., 1996</xref>). Glutathione peroxidase 4 (GPX4) protects the cells from ferroptotic death by reducing toxic PLOOHs to PUFA-containing-phospholipid hydroxides (PL-PUFA (PE)-OH, PLOH in short), with the presence of selenium (<xref ref-type="bibr" rid="B47">Liu et al., 2021</xref>) and GSH (<xref ref-type="bibr" rid="B71">Ursini &#x26; Maiorino, 2020</xref>). While PLOHs appear to be non-ferroptogenic (not ferroptosis-inducing), this marks the end of the brief ferroptosis mechanisms as the homeostasis is achieved.</p>
<p>Ferroptosis has been observed in different pathologies. For example, in Alzheimer&#x2019;s disease that is characterized by prominent brain cell death, &#x3b2;-amyloid plaques and neurofibrillary tangles were investigated, and excess iron accumulation and downregulation of iron exporter, ferroportin1, were observed, thereby explaining the oxidative stress exerted and promoting the AD cognitive impairment (<xref ref-type="bibr" rid="B2">Bao et al., 2021</xref>). In renal ischemia/reperfusion injury (IRI), ferroptosis is proven in the mediation of renal tubule-synchronized necrosis, and a novel third-generation ferrostatin 16&#x2013;86 could rescue or protect the tubular damage that contributes to IRI (<xref ref-type="bibr" rid="B45">Linkermann et al., 2014</xref>). In cancer, particularly in colorectal cancer, it was evident that ferroptosis promotes metabolic rewiring, or the Warburg effect, which favors cancer cell growth, as well as suppresses ferroptosis sensitivity by inducing ROS production and activating nuclear factor erythroid 2-related factor 2 (NRF2) (<xref ref-type="bibr" rid="B91">Yuan et al., 2021</xref>). These are just few examples that ferroptosis correlates with disease progression, and more details about various pathologies can be found in other good articles such as <xref ref-type="bibr" rid="B33">Jiang et al. (2021b)</xref> and <xref ref-type="bibr" rid="B80">Yan et al. (2021)</xref> for readers&#x2019; reference.</p>
</sec>
</sec>
<sec id="s4">
<title>Ferroptosis and epitranscriptomics: neither two monologues nor a mere duologue</title>
<p>Due to technological advancements in investigating epitranscriptomics and firmer theoretical bedrock on the principle of ferroptosis, both topics are gaining escalating heed from scientists. However, the association between epitranscriptomics and ferroptosis has yet been organized. Thence, with reference to the preliminary background knowledge, we summarize some updates on ferroptosis and epitranscriptomic modifications in recent years and attempt to put a new perspective on the investigation of ferroptosis to facilitate the demystification of any connection between epitranscriptomics and ferroptosis.</p>
<sec id="s4-1">
<title>Feed-forward interaction: how do epitranscriptomics shape the niche of ferroptotic homeostasis?</title>
<sec id="s4-1-1">
<title>Ferroptosis and m<sup>6</sup>A</title>
<p>Being the most characterized epitranscriptomic modification, m<sup>6</sup>A has been widely investigated for its relationship with ferroptosis in different pathological phenomena, including cell cycle, drug resistance, biomarkers, or disease signatures. A couple of m<sup>6</sup>A writers, readers, and erasers have been focused to study as a direct or indirect target to mediate ferroptosis, sorted out in <xref ref-type="table" rid="T2">Table 2</xref>. METTL14 upregulation resulted from doxorubicin treatment in AC16 cardiomyocytes and neonatal rat ventricle cardiomyocytes, and m<sup>6</sup>A &#x201c;writing&#x201d; action was observed to be catalyzed on a sponge lncRNA KCNQ1OT1 for miR-7-5p, which cooperated with RNA-binding protein IGF2BP1 to inhibit miR-7-5p activity, leading to transferrin receptor upregulation and iron uptake increase. Such a phenomenon joins the ferroptotic signaling and increases the opportunity of having lipid peroxidation (<xref ref-type="bibr" rid="B93">Zhuang et al., 2021</xref>). Another research echoes with the miR-7-5p and doxorubicin chemoresistance study carried out by <xref ref-type="bibr" rid="B66">Song et al. (2021</xref>) on exosomal miR-4443 and cisplatin resistance in non-small cell lung carcinoma. Tantamount to apoptosis, cisplatin simultaneously acts as a dual trigger of apoptosis and ferroptosis to kill cancer cells (<xref ref-type="bibr" rid="B25">Guo et al., 2018</xref>). On this groundwork, in tumoral and normal tissue-derived exosomes, their team discovered a distinctive expression level of miR-4443 between cisplatin-sensitive and cisplatin-resistant tissues and cell lines, and further functional and bioinformatics studies confirmed that m<sup>6</sup>A writer METTL3 was negatively regulated by miR-4443 overexpression to lower the m<sup>6</sup>A level on ferroptosis-suppressing protein 1 (FSP1), inhibiting its activity to suppress ferroptosis. Bioinformatics analyses on lncRNAs also revealed m<sup>6</sup>A regulators, namely, FMR1, HNRNPC, METTL16, METTL3, and METTL5, were expressed in higher levels than those in ferroptosis low-risk groups (<xref ref-type="bibr" rid="B32">Jiang, W. et al., 2021a</xref>). The aforementioned studies provided evidence that epitranscriptomics are phenomenally involved in ferroptotic disease models, particularly in drug-resistant cancers that have the characteristic to overcome cell death events. As ferroptosis is a new type of PCD, the participation of miRNA, lncRNA, or other types of RNA with distinguished epitranscriptomic features is worth investigating to obtain a complete picture of its disease progress contribution, in order to potentiate clinical relevance for disease manipulation in the future. The theoretical basis on how epitranscriptomics shaped the ferroptosis signaling was also exemplified in pan-cancer <italic>in vitro</italic>, including in hepatocellular carcinoma (<xref ref-type="bibr" rid="B19">Fan et al., 2021</xref>), hepatic stellate cells (<xref ref-type="bibr" rid="B62">Shen et al., 2022</xref>) (<xref ref-type="bibr" rid="B63">Shen et al., 2021</xref>), lung adenocarcinoma (<xref ref-type="bibr" rid="B77">Xu et al., 2022</xref>), and glioblastoma (<xref ref-type="bibr" rid="B67">Sun et al., 2022</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Discovered epitranscriptomic marks on ferroptosis-related proteins.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Disease model</th>
<th align="left">Mechanisms in ferroptosis</th>
<th align="left">Epitranscriptomic mark-associated protein</th>
<th align="left">Discovery</th>
<th align="left">Reference</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Lung cells (A549)</td>
<td align="left">Lipoxygenase pathway, arachidonic acid metabolic process, and response to selenium ion</td>
<td align="left">m6A reader&#x2013;YTHDF2</td>
<td align="left">BPQDs increase the global m6A level and decrease ALKBH5 to promote ferroptosis-related pathways</td>
<td align="left">
<xref ref-type="bibr" rid="B60">Ruan et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Acute myeloid leukemia cell line (TF-1)</td>
<td align="left">GPX4 antioxidant</td>
<td align="left">m6A eraser&#x2013;FTO</td>
<td align="left">In-house GNRa-CSP12 sensitized AML cells to TKIs by FTO-m<sup>6</sup>A hypomethylation on GPX4 to promote ferroptosis</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Du et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">AC16 cardiomyocytes and neonatal rat ventricle cardiomyocytes</td>
<td align="left">Iron uptake ROS production</td>
<td align="left">m<sup>6</sup>A writer&#x2013;METTL14</td>
<td align="left">Doxorubicin induced METTL14 and lncRNA KCNQ1OT1 to inhibit miR-7-5p, triggering the TFRC increase to promote ferroptosis</td>
<td align="left">
<xref ref-type="bibr" rid="B93">Zhuang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Human hepatic malignant and normal cell lines</td>
<td align="left">Cysteine import</td>
<td align="left">m<sup>6</sup>A writer&#x2013;METTL14; m<sup>6</sup>A reader&#x2013;YTHDF2</td>
<td align="left">METTL14 suppression in SLC7A11 and thereafter degradation relied on the YTHDF2&#x2010;dependent pathway were observed under hypoxia</td>
<td align="left">
<xref ref-type="bibr" rid="B19">Fan et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Malignant and normal lung cell lines</td>
<td align="left">Cysteine import</td>
<td align="left">m6A writer&#x2013;METTL3; m6A reader&#x2013;YTHDF1</td>
<td align="left">METTL3 modifies the m<sup>6</sup>A level in SLC7A11 by recruiting YTHDF1 to promote ferroptosis in LUAD.</td>
<td align="left">
<xref ref-type="bibr" rid="B77">Xu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">Human liver tissues</td>
<td align="left">Cysteine import</td>
<td align="left">m<sup>6</sup>A writer&#x2013;METTL4; m6A reader&#x2013;YTHDF1; m6A eraser&#x2013;FTO</td>
<td align="left">METTL4 upregulation and FTO downregulation increase global m<sup>6</sup>A level in BECN1 mRNA that originally inhibit SLC7A11, and the YTHDF1 increase promotes BECN1 stability to inhibit cysteine intake and promote ferroptosis in HSCs</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Shen et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Mice HSCs</td>
<td align="left">Cysteine import</td>
<td align="left">m6A reader&#x2013;YTHDF1; m6A eraser&#x2013;FTO</td>
<td align="left">DHA downregulated FTO to increase m<sup>6</sup>A in BECN1 mRNA, leading to YTHDF1-dependent enhanced stability to inhibit SLC7A11 cysteine&#x2013;glutamate exchange, promoting HSC ferroptosis</td>
<td align="left">
<xref ref-type="bibr" rid="B62">Shen et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">Human glioblastoma cell lines (U87MG and U251)</td>
<td align="left">Cysteine import</td>
<td align="left">m<sup>6</sup>A reader&#x2013;NKAP</td>
<td align="left">NKAP binds to m<sup>6</sup>A in SLC7A11 transcripts and promotes transcriptional splicing and maturation to suppress ferroptosis in glioblastoma cells</td>
<td align="left">
<xref ref-type="bibr" rid="B67">Sun et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">CRC and adenoma tissues</td>
<td align="left">Ferritinophagy</td>
<td align="left">m6A eraser&#x2013;ALKBH5</td>
<td align="left">CircRNA cIARS interacts with ALKBH5 to positively regulate ferritinophagy in SF-treated HCC cells</td>
<td align="left">
<xref ref-type="bibr" rid="B49">Liu et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">BMSCs in mice</td>
<td align="left">Erastin-induced ferroptotic cysteine transport</td>
<td align="left">m5C writer&#x2013;NSUN5</td>
<td align="left">NSUN5 downregulation is correlated with reduced m<sup>5</sup>C in FTH1/FTL, contributing to ferroptosis</td>
<td align="left">
<xref ref-type="bibr" rid="B46">Liu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">Human glioma cell line (U251)</td>
<td align="left">Glutamine metabolism in the antioxidant system</td>
<td align="left">A-to-I editing writer&#x2013;ADAR</td>
<td align="left">ATXN8OS was found to interact with ADAR and downstream interaction with ferroptosis-related targets is suspected to mediate ferroptosis. These targets include GLS2</td>
<td align="left">
<xref ref-type="bibr" rid="B51">Luo et al. (2022)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s4-1-2">
<title>Ferroptosis and other epitranscriptomic marks</title>
<p>A majority of the published articles were m<sup>6</sup>A-based, and there is a huge lack of epitranscriptomic discoveries regarding other marks on ferroptosis. m<sup>5</sup>C is second to m<sup>6</sup>A in terms of the level being explored, and the investigation is still ongoing since we are only scratching the surface of the epitranscriptomic modifications aside from m<sup>6</sup>A (<xref ref-type="bibr" rid="B46">Liu et al., 2022</xref>). In fact, one closely related work that is also one of the most recent discoveries bridging epitranscriptomics and ferroptosis was on m<sup>5</sup>C and its exclusive writer NOP2/Sun RNA methyltransferase 5 (NSUN5). In bone marrow-derived mesenchymal stem cells (BMSCs), Liu&#x2019;s group reported a notable downregulation of NSUN5 in ferroptotic cells and unveiled the enhancement of Fe<sup>2&#x2b;</sup> ions in NSUN5 depletion <italic>in vitro</italic>. More importantly, NSUN5 overexpression, which was later confirmed as its methylating action on 5&#x2032;UTR/3&#x2032;UTR of ferritin heavy chain/light chain (FTH1/FTL), was correlated with TRAP1 recruitment on FTH1/FTL, a protein that governs the intracellular entry of iron ions, confirmed by LC-MS and co-immunoprecipitation (co-IP). Liu&#x2019;s group has impacted both the fields of ferroptosis and epitranscriptomics by expanding the discussion to other base modifications other than the predominant m<sup>6</sup>A. Meanwhile, further studies on other disease or cell models, or more superior 3D culture and organoid models, necessitate to be carried out for proof-of-concept.</p>
<p>In addition to m<sup>5</sup>C, in triple-negative breast cancer patients, investigating the tumor microenvironment (TME) guided the discovery of a rare epitranscriptomic feature that serves as a potential biomarker in microniches. Using spatial epitranscriptomic analyses on tumor microniches, <xref ref-type="bibr" rid="B40">Lee et al. (2022</xref>) sought to profile A-to-I editome and identified high A-to-I editing in GPX4 variants in IF-stained tissues full-length transcriptome. This result fitted their hypothesis that cancer stem cells (CSCs) contain high A-to-I editing characteristic for their niche shaping, and the future validation work can potentiate the druggability of such epitranscriptomic feature in this ferroptotic-signaling protein.</p>
</sec>
</sec>
<sec id="s4-2">
<title>Feedback interaction one: how will lipid ROS accumulation potentially influence the nuanced epitranscriptomic features back?</title>
<p>Cellular signaling in biological systems evolved with harmonized crosstalk and attempting to inspect the entirety via a single chronological representation remains laborious to reach the finality. It becomes interesting whether the accumulating lipid ROS being non-eliminated construct a feedback influence on the epitranscriptomic marks. Oxygen atoms in &#x2013;OH groups and phosphodiester backbone are the most vulnerable to be subjected to chemical damage or oxidation (<xref ref-type="bibr" rid="B46">Liu et al., 2022</xref>), and ROS onslaught has demonstrated evidently in mutations (<xref ref-type="bibr" rid="B55">Niedernhofer et al., 2003</xref>), cell arrest (<xref ref-type="bibr" rid="B12">Dixon &#x26; Stockwell, 2014</xref>), and epitranscriptomic induction (<xref ref-type="bibr" rid="B38">Kumar &#x26; Mohapatra, 2021</xref>). Particularly in cancer, m<sup>6</sup>A induction has been studied and reviewed in response to the production of ROS, and a biphasic and conflicting effect on tumor growth, intriguingly, has been noticed (<xref ref-type="bibr" rid="B5">Chio &#x26; Tuveson, 2017</xref>) (<xref ref-type="bibr" rid="B81">Yang &#x26; Chen, 2021</xref>). The potential ROS effect in ferroptosis via epitranscriptomic mediation is hence plausible.</p>
<p>Since the concept of &#x201c;global m<sup>6</sup>A level can be ROS-induced&#x201d; was revealed, one ROS-induced post-translational regulation on m<sup>6</sup>A demethylase was discovered recently (<xref ref-type="bibr" rid="B88">Yu et al., 2021</xref>). In this study by Yu et al., human cell lines with high m<sup>6</sup>A induced by ROS and determined by m<sup>6</sup>A-seq, were employed to survey the intrinsic mechanism that contributed to the elevation, where SUMOylation in m<sup>6</sup>A demethylase ALKBH5 was found to be associated using comet analysis, a single-cell gel electrophoresis assay that helps determine DNA damage and repair equilibrium at a single cell level. Particularly, SUMOylation-deficiency in ALKBH5 led to weakened DNA repair in H<sub>2</sub>O<sub>2</sub>-induced DNA damage, in other words, SUMOylation in ALKBH5 is essential in the increase of global m<sup>6</sup>A level by limiting the activity of m<sup>6</sup>A erasers. As ROS also joins the ferroptotic signaling and can lead to ferroptotic cell death, how ROS can potentially construct a stressful environment and add on epitranscriptomic modifications of ferroptosis proteins remains to be extrapolated. Having a feedback loop discovered that thrusts in the cell death process offer a great potential to manipulate the pathways, and the prospects of targeting ferroptosis in therapeutic settings await.</p>
</sec>
<sec id="s4-3">
<title>Feedback interaction two: how does iron imbalance contribute to an epitranscriptomic mark level?</title>
<p>
<xref ref-type="bibr" rid="B10">Dixon et al. (2012</xref>) extensively acknowledged the importance of iron in its mediation to the PCD event by coining the &#x201c;ferro-&#x201d; in the nomenclature of the iron-driven cell death, ferroptosis, assisted by the Nomenclature Committee of Cell Death (NCCD). Before then, prominent iron overload was observed among pathologies, such as hereditary hemochromatosis, along with the complications manifested, including organ damage, hypothyroidism, and hypogonadism. Managing iron homeostasis, thence, is necessitated from a medical standpoint, combined with the fact that ferroptosis is also dependent on intracellular iron status. In addition, <italic>en route</italic> to the research on how important iron to ferroptosis is, we also discovered some connections between iron and epitranscriptomic marks upon rummaging articles. We aimed to address the potential association of iron status and epitranscriptomics in ferroptosis and provided upcoming possible research directions to facilitate the elucidation of this mystery.</p>
<p>The fact that heme groups and Fe&#x2013;S clusters are frequently under the attack of various kinds of ROS is well known (<xref ref-type="bibr" rid="B31">Imlay, 2006</xref>). This increases the intracellular level of Fe<sup>2&#x2b;</sup> apart from the LIP, though the LIP serves as the predominant source of Fe<sup>2&#x2b;</sup>. In fact, perturbations of epitranscriptomics that affect the iron level or iron metabolism have been shown via some direct studies. In a hypopharyngeal squamous cell carcinoma (HPSCC) study by <xref ref-type="bibr" rid="B86">Ye et al. (2020</xref>), transcriptomic analyses including m<sup>6</sup>A-seq, RNA-seq, and RIP-seq identified m<sup>6</sup>A reader YTHDF1&#x2019;s downstream target transferrin receptor (TFRC), simultaneously linking to poor prognosis in postoperative platinum-based chemoradiotherapy (CCT) or radiation patients in an m<sup>6</sup>A-dependent manner. HPSCC patients with intratumorally elevated Fe<sup>2&#x2b;</sup> were also shown upregulated YTHDF1 expression, and knockdown YTHDF1 in HPSCC cells proved the suppression of cell proliferation and migration ability. Taken together, as YTHDF1 modifies TFRC mRNA in cytosol and modulates transcriptomic stability and fate, relationships between an RMP and an iron metabolism participant were speculated by this pioneering work. Additionally, a pancreatic ductal adenocarcinoma (PDAC) study by <xref ref-type="bibr" rid="B30">Huang et al. (2021</xref>) aimed at elucidating the connection of ALKBH5 and iron metabolism, concretely on mRNAs encoding ubiquitin ligase FBXL5 and iron importers SLC25A28 and SLC25A37. ALKBH5 was identified to be mechanistically associated to the RNA decay event for FBXL5, and the team has divulged its unique prognostic ability among multiple m<sup>6</sup>A regulators analyzed in the study. Considering FBXL5-IRP2 serves as the cardinal part to iron metabolism (<xref ref-type="bibr" rid="B74">Wang et al., 2020</xref>), this study adds on the evidence of connecting epitranscriptomic-mediated iron metabolism since the bridge between FBXL5 and ALKBH5 can now be surmised through transcriptomic analyses, and further validation work awaits to confirm.</p>
<sec id="s4-3-1">
<title>Prospect and unaddressed questions</title>
<p>Yet, tracing back to the fact that excess intracellular iron leads to disturbed redox imbalance, and hence impaired cellular metabolism, we shall also pay heed to the crosstalk between iron metabolism and epitranscriptomics. Despite limited direct studies on the biological functions, some RMPs are reported to be affected by iron levels. m<sup>6</sup>A demethylase ALKBH5 was Fe<sup>2&#x2b;</sup>-dependent, proven in an optimization research study for downstream screening work by <xref ref-type="bibr" rid="B41">Li et al. (2016</xref>). Therefore, it leaves us with the following questions on 1) how much iron level deviation intracellularly can drive impaired ALKBH5 function; 2) how much Fe<sup>2&#x2b;</sup> perturbations can lead to redox imbalance, followed by the epitranscriptomic mark writing on RMPS that constitutes to a crosstalk signaling; and 3) what are the signaling paradigms required for iron-driven/ROS-induced epitranscriptomic mark writing and the potential involvement to ferroptosis. There are still many unsolved questions that build around the biological or biomedical conjectures on ferroptosis and epitranscriptomics that begin with iron imbalance and ROS induction. Addressing these outstanding questions shall help determine the direct involvement of distinct components in ferroptosis.</p>
</sec>
</sec>
</sec>
<sec id="s5">
<title>Concluding remarks</title>
<p>In retrospect, investigating a new topic in science has always been regarded as preposterous at the beginning, and the journey of vindication seems to be life-long and with collaborative efforts. Epitranscriptomics have indeed experienced a dejected period due to the lack of technological advancement, but the value <italic>per se</italic> is tantamount to epigenetic modifications owing to its importance in governing the ultimate phenotype of a gene. It is hard for us to ignore the participation of such element being pervasive on gene expression in ferroptosis, a new type of PCD discovered just in recent decades, and is still being explored for its potential clinical relevance. As the evidence regarding epitranscriptomics and ferroptosis began to pile up, with the associated indirect studies on the passengers of both, RMPs or lipid ROS, <italic>videlicet</italic>, we offered additional perspectives for readers to define the pathways of ferroptosis with respect to epitranscriptomic modifications, and thus to provide foreseeable opportunities toward comprehensiveness of such topics.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author contributions</title>
<p>JC conceived and wrote the manuscript. GD, YD, and NW commented and provided expertise in ferroptosis. SN secured funding. YD and SN supervised the study and revised the manuscript.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This project was supported by research funds from the Lim Peng Suan Charitable Trust Research Fund and National Natural Science Foundation of China (81871900). This project was supported in part by the Hong Kong Research Grants Council Area of Excellence Scheme (Ref. AoE/M-401/20) and Research Impact Fund (Ref. R4017-18).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aggarwal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tuli</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Varol</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thakral</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yerer</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Sak</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements</article-title>. <source>Biomolecules</source> <volume>9</volume> (<issue>11</issue>), <fpage>E735</fpage>. <pub-id pub-id-type="doi">10.3390/biom9110735</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X. T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer&#x27;s disease</article-title>. <source>Cell Death Differ.</source> <volume>28</volume> (<issue>5</issue>), <fpage>1548</fpage>&#x2013;<lpage>1562</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-020-00685-9</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boccaletto</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Machnicka</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Purta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Piatkowski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Baginski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wirecki</surname>
<given-names>T. K.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Modomics: A database of RNA modification pathways. 2017 update</article-title>. <source>Nucleic Acids Res.</source> <volume>46</volume> (<issue>D1</issue>), <fpage>D303</fpage>&#x2013;<lpage>D307</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1030</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ceballos-Picot</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Witko-Sarsat</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Merad-Boudia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Thevenin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jaudon</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>1996</year>). <article-title>Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure</article-title>. <source>Free Radic. Biol. Med.</source> <volume>21</volume> (<issue>6</issue>), <fpage>845</fpage>&#x2013;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.1016/0891-5849(96)00233-x</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chio</surname>
<given-names>I. I. C.</given-names>
</name>
<name>
<surname>Tuveson</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>ROS in cancer: The burning question</article-title>. <source>Trends Mol. Med.</source> <volume>23</volume> (<issue>5</issue>), <fpage>411</fpage>&#x2013;<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2017.03.004</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cozen</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Quartley</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Hrabeta-Robinson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Phizicky</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>T. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>ARM-Seq: AlkB-facilitated RNA methylation sequencing reveals a complex landscape of modified tRNA fragments</article-title>. <source>Nat. Methods</source> <volume>12</volume> (<issue>9</issue>), <fpage>879</fpage>&#x2013;<lpage>884</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3508</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>F. F.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>F. W.</given-names>
</name>
</person-group> (<year>1957</year>). <article-title>Ribonucleic acids from yeast which contain a fifth nucleotide</article-title>. <source>J. Biol. Chem.</source> <volume>227</volume> (<issue>2</issue>), <fpage>907</fpage>&#x2013;<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)70770-9</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Destefanis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Avsar</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Groza</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Romitelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torrini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pir</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A mark of disease: How mRNA modifications shape genetic and acquired pathologies</article-title>. <source>RNA</source> <volume>27</volume> (<issue>4</issue>), <fpage>367</fpage>&#x2013;<lpage>389</lpage>. <pub-id pub-id-type="doi">10.1261/rna.077271.120</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias Amoedo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dard</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sarlak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mahfouf</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rousseau</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Targeting human lung adenocarcinoma with a suppressor of mitochondrial superoxide production</article-title>. <source>Antioxid. Redox Signal.</source> <volume>33</volume> (<issue>13</issue>), <fpage>883</fpage>&#x2013;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2019.7892</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Lemberg</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Lamprecht</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zaitsev</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Gleason</surname>
<given-names>C. E.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Ferroptosis: An iron-dependent form of nonapoptotic cell death</article-title>. <source>Cell</source> <volume>149</volume> (<issue>5</issue>), <fpage>1060</fpage>&#x2013;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>D. N.</given-names>
</name>
<name>
<surname>Welsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Hayano</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis</article-title>. <source>Elife</source> <volume>3</volume>, <fpage>e02523</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.02523</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The role of iron and reactive oxygen species in cell death</article-title>. <source>Nat. Chem. Biol.</source> <volume>10</volume> (<issue>1</issue>), <fpage>9</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1416</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Proneth</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Panzilius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition</article-title>. <source>Nat. Chem. Biol.</source> <volume>13</volume> (<issue>1</issue>), <fpage>91</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2239</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lessnick</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells</article-title>. <source>Cancer Cell</source> <volume>3</volume> (<issue>3</issue>), <fpage>285</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/s1535-6108(03)00050-3</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dominissini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Moshitch-Moshkovitz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amariglio</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rechavi</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Transcriptome-wide mapping of N&#x2076;-Methyladenosine by m&#x2076;A-seq.</article-title> <source>Methods Enzymol.</source> <volume>560</volume>, <fpage>131</fpage>&#x2013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/bs.mie.2015.03.001</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Gold nanorods exhibit intrinsic therapeutic activity via controlling N6-methyladenosine-based epitranscriptomics in acute myeloid leukemia</article-title>. <source>ACS Nano</source> <volume>15</volume>, <fpage>17689</fpage>&#x2013;<lpage>17704</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c05547</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunin-Horkawicz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Czerwoniec</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gajda</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Feder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grosjean</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bujnicki</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Modomics: A database of RNA modification pathways</article-title>. <source>Nucleic Acids Res.</source> <volume>34</volume>, <fpage>D145</fpage>&#x2013;<lpage>D149</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkj084</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eagle</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1955</year>). <article-title>Nutrition needs of mammalian cells in tissue culture</article-title>. <source>Science</source> <volume>122</volume> (<issue>3168</issue>), <fpage>501</fpage>&#x2013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1126/science.122.3168.501</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11</article-title>. <source>J. Cell. Mol. Med.</source> <volume>25</volume> (<issue>21</issue>), <fpage>10197</fpage>&#x2013;<lpage>10212</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.16957</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forcina</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>GPX4 at the crossroads of lipid homeostasis and ferroptosis</article-title>. <source>Proteomics</source> <volume>19</volume> (<issue>18</issue>), <fpage>e1800311</fpage>. <pub-id pub-id-type="doi">10.1002/pmic.201800311</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Behm</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>RNA modifications modulate gene expression during development</article-title>. <source>Science</source> <volume>361</volume> (<issue>6409</issue>), <fpage>1346</fpage>&#x2013;<lpage>1349</lpage>. <pub-id pub-id-type="doi">10.1126/science.aau1646</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaschler</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Linkermann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis</article-title>. <source>ACS Chem. Biol.</source> <volume>13</volume> (<issue>4</issue>), <fpage>1013</fpage>&#x2013;<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.8b00199</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>W. V.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Schaening</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Messenger RNA modifications: Form, distribution, and function</article-title>. <source>Science</source> <volume>352</volume> (<issue>6292</issue>), <fpage>1408</fpage>&#x2013;<lpage>1412</lpage>. <pub-id pub-id-type="doi">10.1126/science.aad8711</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perez-Gallardo</surname>
<given-names>R. V.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Diaz-Perez</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Cortes-Rojo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meza Carmen</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Malfunctioning of the iron-sulfur cluster assembly machinery in Saccharomyces cerevisiae produces oxidative stress via an iron-dependent mechanism, causing dysfunction in respiratory complexes</article-title>. <source>PLoS One</source> <volume>9</volume> (<issue>10</issue>), <fpage>e111585</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0111585</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Ferroptosis: A novel anti-tumor action for cisplatin</article-title>. <source>Cancer Res. Treat.</source> <volume>50</volume> (<issue>2</issue>), <fpage>445</fpage>&#x2013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.4143/crt.2016.572</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hawley</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Jaffrey</surname>
<given-names>S. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Transcriptome-wide mapping of m(6) A and m(6) Am at single-nucleotide resolution using miCLIP</article-title>. <source>Curr. Protoc. Mol. Biol.</source> <volume>126</volume> (<issue>1</issue>), <fpage>e88</fpage>. <pub-id pub-id-type="doi">10.1002/cpmb.88</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heiss</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borland</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoluc</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kellner</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Quantification of modified nucleosides in the context of NAIL-MS</article-title>. <source>Methods Mol. Biol.</source> <volume>2298</volume>, <fpage>279</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-1374-0_18</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helm</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Motorin</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Detecting RNA modifications in the epitranscriptome: Predict and validate</article-title>. <source>Nat. Rev. Genet.</source> <volume>18</volume> (<issue>5</issue>), <fpage>275</fpage>&#x2013;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1038/nrg.2016.169</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinson</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>L. P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Mechanisms of acetaminophen-induced liver necrosis</article-title>. <source>Handb. Exp. Pharmacol.</source> <volume>196</volume>, <fpage>369</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-00663-0_12</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>W. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>RNA m(6)A demethylase ALKBH5 protects against pancreatic ductal adenocarcinoma via targeting regulators of iron metabolism</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>9</volume>, <fpage>724282</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.724282</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imlay</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Iron-sulphur clusters and the problem with oxygen</article-title>. <source>Mol. Microbiol.</source> <volume>59</volume> (<issue>4</issue>), <fpage>1073</fpage>&#x2013;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05028.x</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Ferroptosis-related long non-coding RNA signature contributes to the prediction of prognosis outcomes in head and neck squamous cell carcinomas</article-title>. <source>Front. Genet.</source> <volume>12</volume>, <fpage>785839</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2021.785839</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>Ferroptosis: Mechanisms, biology and role in disease</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>22</volume> (<issue>4</issue>), <fpage>266</fpage>&#x2013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-00324-8</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaludercic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Di Lisa</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mitochondrial ROS formation in the pathogenesis of diabetic cardiomyopathy</article-title>. <source>Front. Cardiovasc. Med.</source> <volume>7</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2020.00012</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alemu</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gantman</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Fak</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Mele</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>A majority of m6A residues are in the last exons, allowing the potential for 3&#x27; UTR regulation</article-title>. <source>Genes Dev.</source> <volume>29</volume> (<issue>19</issue>), <fpage>2037</fpage>&#x2013;<lpage>2053</lpage>. <pub-id pub-id-type="doi">10.1101/gad.269415.115</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoddami</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Identification of direct targets and modified bases of RNA cytosine methyltransferases</article-title>. <source>Nat. Biotechnol.</source> <volume>31</volume> (<issue>5</issue>), <fpage>458</fpage>&#x2013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2566</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koseki</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamagata</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shimamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Motooka</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Distinct methylation levels of mature microRNAs in gastrointestinal cancers</article-title>. <source>Nat. Commun.</source> <volume>10</volume> (<issue>1</issue>), <fpage>3888</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-11826-1</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mohapatra</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Deciphering epitranscriptome: Modification of mRNA bases provides a new perspective for post-transcriptional regulation of gene expression</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>9</volume>, <fpage>628415</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.628415</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lachaier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Louandre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Godin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saidak</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Baert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Diouf</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors</article-title>. <source>Anticancer Res.</source> <volume>34</volume> (<issue>11</issue>), <fpage>6417</fpage>&#x2013;<lpage>6422</lpage>. </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches</article-title>. <source>Nat. Commun.</source> <volume>13</volume> (<issue>1</issue>), <fpage>2540</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-30299-3</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hajian</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Seitova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>A radioactivity-based assay for screening human m6A-RNA methyltransferase, METTL3-METTL14 complex, and demethylase ALKBH5</article-title>. <source>J. Biomol. Screen.</source> <volume>21</volume> (<issue>3</issue>), <fpage>290</fpage>&#x2013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1177/1087057115623264</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>N(6)-Methyladenosine modulates nonsense-mediated mRNA decay in human glioblastoma</article-title>. <source>Cancer Res.</source> <volume>79</volume> (<issue>22</issue>), <fpage>5785</fpage>&#x2013;<lpage>5798</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-2868</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z. T.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ferroptosis: Past, present and future</article-title>. <source>Cell Death Dis.</source> <volume>11</volume> (<issue>2</issue>), <fpage>88</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-2298-2</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q. N.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma</article-title>. <source>Mol. Cancer</source> <volume>18</volume> (<issue>1</issue>), <fpage>112</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-019-1038-7</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linkermann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Himmerkus</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mulay</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Dewitz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Zen</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Synchronized renal tubular cell death involves ferroptosis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>111</volume> (<issue>47</issue>), <fpage>16836</fpage>&#x2013;<lpage>16841</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1415518111</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bie</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The NSUN5-FTH1/FTL pathway mediates ferroptosis in bone marrow-derived mesenchymal stem cells</article-title>. <source>Cell Death Discov.</source> <volume>8</volume> (<issue>1</issue>), <fpage>99</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-022-00902-z</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Se improves GPX4 expression and SOD activity to alleviate heat-stress-induced ferroptosis-like death in goat mammary epithelial cells</article-title>. <source>Anim. Cells Syst.</source> <volume>25</volume> (<issue>5</issue>), <fpage>283</fpage>&#x2013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1080/19768354.2021.1988704</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Parisien</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions</article-title>. <source>Nature</source> <volume>518</volume> (<issue>7540</issue>), <fpage>560</fpage>&#x2013;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1038/nature14234</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Circular RNA cIARS regulates ferroptosis in HCC cells through interacting with RNA binding protein ALKBH5</article-title>. <source>Cell Death Discov.</source> <volume>6</volume>, <fpage>72</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-020-00306-x</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louandre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ezzoukhry</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Godin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Barbare</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Maziere</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Chauffert</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib</article-title>. <source>Int. J. Cancer</source> <volume>133</volume> (<issue>7</issue>), <fpage>1732</fpage>&#x2013;<lpage>1742</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.28159</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Long non-coding RNA ATXN8OS promotes ferroptosis and inhibits the temozolomide-resistance of gliomas through the ADAR/GLS2 pathway</article-title>. <source>Brain Res. Bull.</source> <volume>186</volume>, <fpage>27</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2022.04.005</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machnicka</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Milanowska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Osman Oglou</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Purta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kurkowska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Olchowik</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Modomics: A database of RNA modification pathways--2013 update</article-title>. <source>Nucleic Acids Res.</source> <volume>41</volume>, <fpage>D262</fpage>&#x2013;<lpage>D267</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1007</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manoharan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Abiramasundari</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Essa</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Akbar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akbar</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The role of reactive oxygen species in the pathogenesis of alzheimer&#x27;s disease, Parkinson&#x27;s disease, and huntington&#x27;s disease: A mini review</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2016</volume>, <fpage>8590578</fpage>. <pub-id pub-id-type="doi">10.1155/2016/8590578</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nie</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Rnawre: A resource of writers, readers and erasers of RNA modifications</article-title>. <source>Database</source> <volume>2020</volume>, <fpage>baaa049</fpage>. <pub-id pub-id-type="doi">10.1093/database/baaa049</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niedernhofer</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Rouzer</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Marnett</surname>
<given-names>L. J.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells</article-title>. <source>J. Biol. Chem.</source> <volume>278</volume> (<issue>33</issue>), <fpage>31426</fpage>&#x2013;<lpage>31433</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M212549200</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Francisco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Varanda</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>M. A. S.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Impact of tRNA modifications and tRNA-modifying enzymes on proteostasis and human disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>12</issue>), <fpage>E3738</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19123738</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>1974</year>). <article-title>Existence of methylated messenger RNA in mouse L cells</article-title>. <source>Cell</source> <volume>1</volume>, <fpage>37</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(74)90153-6</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rana</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Ankri</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Reviving the RNA world: An insight into the appearance of RNA methyltransferases</article-title>. <source>Front. Genet.</source> <volume>7</volume>, <fpage>99</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2016.00099</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranjan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leidel</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The epitranscriptome in translation regulation: mRNA and tRNA modifications as the two sides of the same coin?</article-title> <source>FEBS Lett.</source> <volume>593</volume> (<issue>13</issue>), <fpage>1483</fpage>&#x2013;<lpage>1493</lpage>. <pub-id pub-id-type="doi">10.1002/1873-3468.13491</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>RNA m6A modification alteration by black phosphorus quantum dots regulates cell ferroptosis: Implications for nanotoxicological assessment</article-title>. <source>Small Methods</source> <volume>5</volume> (<issue>3</issue>), <fpage>e2001045</fpage>. <pub-id pub-id-type="doi">10.1002/smtd.202001045</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gasperi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Begley</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Nevins</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Dedon</surname>
<given-names>P. C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Detecting the epitranscriptome</article-title>. <source>Wiley Interdiscip. Rev. RNA</source> <volume>12</volume> (<issue>6</issue>), <fpage>e1663</fpage>. <pub-id pub-id-type="doi">10.1002/wrna.1663</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>m(6)A methylation is required for dihydroartemisinin to alleviate liver fibrosis by inducing ferroptosis in hepatic stellate cells</article-title>. <source>Free Radic. Biol. Med.</source> <volume>182</volume>, <fpage>246</fpage>&#x2013;<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.02.028</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>N(6)-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells</article-title>. <source>Redox Biol.</source> <volume>47</volume>, <fpage>102151</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2021.102151</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers</article-title>. <source>Mol. Cell</source> <volume>74</volume> (<issue>4</issue>), <fpage>640</fpage>&#x2013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2019.04.025</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Epitranscriptomics and epiproteomics in cancer drug resistance: Therapeutic implications</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>5</volume> (<issue>1</issue>), <fpage>193</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00300-w</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis</article-title>. <source>Life Sci.</source> <volume>276</volume>, <fpage>119399</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2021.119399</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m(6)A-dependent manner</article-title>. <source>Cell Death Dis.</source> <volume>13</volume> (<issue>1</issue>), <fpage>73</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-04524-2</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The expanding world of tRNA modifications and their disease relevance</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>22</volume> (<issue>6</issue>), <fpage>375</fpage>&#x2013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-021-00342-0</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terajima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yoshitane</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shimba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>ADARB1 catalyzes circadian A-to-I editing and regulates RNA rhythm</article-title>. <source>Nat. Genet.</source> <volume>49</volume> (<issue>1</issue>), <fpage>146</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3731</pub-id> </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tien Kuo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Savaraj</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers</article-title>. <source>Mol. Carcinog.</source> <volume>45</volume> (<issue>9</issue>), <fpage>701</fpage>&#x2013;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1002/mc.20240</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ursini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maiorino</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Lipid peroxidation and ferroptosis: The role of GSH and GPx4</article-title>. <source>Free Radic. Biol. Med.</source> <volume>152</volume>, <fpage>175</fpage>&#x2013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.02.027</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visvanathan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Arivazhagan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Santosh</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance</article-title>. <source>Oncogene</source> <volume>37</volume> (<issue>4</issue>), <fpage>522</fpage>&#x2013;<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2017.351</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Buettner</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>C. P.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Free radical-mediated lipid peroxidation in cells: Oxidizability is a function of cell lipid bis-allylic hydrogen content</article-title>. <source>Biochemistry</source> <volume>33</volume> (<issue>15</issue>), <fpage>4449</fpage>&#x2013;<lpage>4453</lpage>. <pub-id pub-id-type="doi">10.1021/bi00181a003</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rajan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Canarie</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Simoneschi</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>FBXL5 regulates IRP2 stability in iron homeostasis via an oxygen-responsive [2Fe2S] cluster</article-title>. <source>Mol. Cell</source> <volume>78</volume> (<issue>1</issue>), <fpage>31</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2020.02.011</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Chromatin and transcriptional regulation by reversible RNA methylation</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>70</volume>, <fpage>109</fpage>&#x2013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2020.11.005</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sachsenberg</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Santos-Rosa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kohlbacher</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kouzarides</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A computational platform for high-throughput analysis of RNA sequences and modifications by mass spectrometry</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>926</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-14665-7</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m(6)A modification</article-title>. <source>Cancer Cell Int.</source> <volume>22</volume> (<issue>1</issue>), <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-021-02433-6</pub-id> </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Multi-omic analyses of the m(5)C regulator ALYREF reveal its essential roles in hepatocellular carcinoma</article-title>. <source>Front. Oncol.</source> <volume>11</volume>, <fpage>633415</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2021.633415</pub-id> </citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yagoda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>von Rechenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zaganjor</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>D. J.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels</article-title>. <source>Nature</source> <volume>447</volume> (<issue>7146</issue>), <fpage>864</fpage>&#x2013;<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1038/nature05859</pub-id> </citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>H. F.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tuo</surname>
<given-names>Q. Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Belaidi</surname>
<given-names>A. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Ferroptosis: Mechanisms and links with diseases</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>6</volume> (<issue>1</issue>), <fpage>49</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00428-9</pub-id> </citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cross-talk between oxidative stress and m(6)A RNA methylation in cancer</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2021</volume>, <fpage>6545728</fpage>. <pub-id pub-id-type="doi">10.1155/2021/6545728</pub-id> </citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>SriRamaratnam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Welsch</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viswanathan</surname>
<given-names>V. S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Regulation of ferroptotic cancer cell death by GPX4</article-title>. <source>Cell</source> <volume>156</volume> (<issue>1-2</issue>), <fpage>317</fpage>&#x2013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.12.010</pub-id> </citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells</article-title>. <source>Chem. Biol.</source> <volume>15</volume> (<issue>3</issue>), <fpage>234</fpage>&#x2013;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2008.02.010</pub-id> </citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>N6-methyladenine modification in noncoding RNAs and its function in cancer</article-title>. <source>Biomark. Res.</source> <volume>8</volume> (<issue>1</issue>), <fpage>61</fpage>. <pub-id pub-id-type="doi">10.1186/s40364-020-00244-x</pub-id> </citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Oxidative stress-mediated atherosclerosis: Mechanisms and therapies</article-title>. <source>Front. Physiol.</source> <volume>8</volume>, <fpage>600</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.00600</pub-id> </citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>YTHDF1-enhanced iron metabolism depends on TFRC m(6)A methylation</article-title>. <source>Theranostics</source> <volume>10</volume> (<issue>26</issue>), <fpage>12072</fpage>&#x2013;<lpage>12089</lpage>. <pub-id pub-id-type="doi">10.7150/thno.51231</pub-id> </citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The epitranscriptome of long noncoding RNAs in metabolic diseases</article-title>. <source>Clin. Chim. Acta.</source> <volume>515</volume>, <fpage>80</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2021.01.001</pub-id> </citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bungert</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response</article-title>. <source>Nucleic Acids Res.</source> <volume>49</volume> (<issue>10</issue>), <fpage>5779</fpage>&#x2013;<lpage>5797</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkab415</pub-id> </citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>B. F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Liquid chromatography-mass spectrometry for analysis of RNA adenosine methylation</article-title>. <source>Methods Mol. Biol.</source> <volume>1562</volume>, <fpage>33</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-6807-7_3</pub-id> </citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Identification of ACSL4 as a biomarker and contributor of ferroptosis</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>478</volume> (<issue>3</issue>), <fpage>1338</fpage>&#x2013;<lpage>1343</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.08.124</pub-id> </citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhuge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Iron regulates the Warburg effect and ferroptosis in colorectal cancer</article-title>. <source>Front. Oncol.</source> <volume>11</volume>, <fpage>614778</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2021.614778</pub-id> </citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J. X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Aberrant ROS mediate cell cycle and motility in colorectal cancer cells through an oncogenic CXCL14 signaling pathway</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>764015</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.764015</pub-id> </citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis</article-title>. <source>Cell Biol. Toxicol.</source> <pub-id pub-id-type="doi">10.1007/s10565-021-09660-7</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>